Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$120,000.00

Exploiting the Receptor Tyrosine Kinase MER for the Targeted Therapy of Colorectal Cancer

EF 2013-14

Résumé
Background: Survival in metastatic colorectal cancer (CRC) remains limited with current treatments. New therapies are needed in CRC, especially those that target key cancer pathways. The signalling protein MER promotes cell growth and has been implicated in several cancers. Recently, Dr. Eckhardt and her team demonstrated that MER and its associated signalling pathway are also relevant in CRC. Further, drugs that specifically block MER have been generated, and data showed that they may effectively impair tumour growth. However, these novel MER inhibitors have not been tested in CRC. Aims: The primary aim of this project is to evaluate the anti-tumour efficacy of the MER inhibitor UNC2371 in CRC, using both cell lines and mouse models called patient-derived tumour xenografts (PDTX). The PDTX carry human colorectal tumours, and as such, most closely recapitulate cancer behaviour within a human. The secondary aim is to develop and test the feasibility of a 'personalized' approach for the use of UNC2371. We hypothesize that different tumours have intrinsically different genetic characteristics that confer variable responses to MER inhibition. It may be possible to identify a set of biomarkers that predicts the subset of tumours most responsive to UNC2371. Methods: We will initially characterize the features of CRC cell lines exposed to UNC2371. Then, using genomic technologies, the genetic profile of cancer cells associated with drug response will be determined. Finally, we will compare the efficacy of UNC2371 vs. conventional chemotherapy in PDTX models, while incorporating a selective/personalized strategy to include only PDTX predicted to be drug-sensitive. Significance: This is the first study to examine MER as a potential new treatment strategy in CRC using the drug UNC2371. Importantly, if our results establish benefits of UNC2371 in CRC experimental models, this drug will be further tested in a cohort of patients with metastatic CRC in an early human trial.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Colorado, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
300344
Name
Wong Kit Man
Region
Colorado
Country
United States of America
Orgtype
Research Institution
Partnername
Canadian Association of Medical Oncologists (Ottawa)
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Health Professional Awards - Fellowships
Projecttitle
Exploiting the Receptor Tyrosine Kinase MER for the Targeted Therapy of Colorectal Cancer
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cancer Genomics; Colorectal Cancer; Drug Development; Mer Tyrosine Kinase; Patient-Derived Tumour Xenografts; Personalized Therapy; Targeted Therapy; Tyrosine Kinase Inhibitor
Abstract
Background: Survival in metastatic colorectal cancer (CRC) remains limited with current treatments. New therapies are needed in CRC, especially those that target key cancer pathways. The signalling protein MER promotes cell growth and has been implicated in several cancers. Recently, Dr. Eckhardt and her team demonstrated that MER and its associated signalling pathway are also relevant in CRC. Further, drugs that specifically block MER have been generated, and data showed that they may effectively impair tumour growth. However, these novel MER inhibitors have not been tested in CRC. Aims: The primary aim of this project is to evaluate the anti-tumour efficacy of the MER inhibitor UNC2371 in CRC, using both cell lines and mouse models called patient-derived tumour xenografts (PDTX). The PDTX carry human colorectal tumours, and as such, most closely recapitulate cancer behaviour within a human. The secondary aim is to develop and test the feasibility of a 'personalized' approach for the use of UNC2371. We hypothesize that different tumours have intrinsically different genetic characteristics that confer variable responses to MER inhibition. It may be possible to identify a set of biomarkers that predicts the subset of tumours most responsive to UNC2371. Methods: We will initially characterize the features of CRC cell lines exposed to UNC2371. Then, using genomic technologies, the genetic profile of cancer cells associated with drug response will be determined. Finally, we will compare the efficacy of UNC2371 vs. conventional chemotherapy in PDTX models, while incorporating a selective/personalized strategy to include only PDTX predicted to be drug-sensitive. Significance: This is the first study to examine MER as a potential new treatment strategy in CRC using the drug UNC2371. Importantly, if our results establish benefits of UNC2371 in CRC experimental models, this drug will be further tested in a cohort of patients with metastatic CRC in an early human trial.
Competitiondate
201311
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Wong, Kit Man
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~